View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 16, 2022

Prothione capsules reduce Covid-19 viral load in Phase II trial

The antiviral offered a decline in time to clinical resolution as described by the time to achieve three negative RT-PCR tests.

Prothione has reported positive data from a Phase II clinical trial, where its capsules offered a statistically significant decline in Covid-19 viral load.

A novel antiviral, Prothione capsule has greater clinical efficacy and pan-Covid-19 design properties that maintain activity with a favourable safety profile. 

It has three amino acids that can boost intracellular glutathione, lower oxidative stress and hinder inflammatory reactions during Covid-19.

The proof of concept, randomised, double-blind, placebo-controlled trial analysed the safety and efficacy of Prothione capsules to treat mild to moderate Covid-19.

Findings showed that the subjects who received the capsules had a decline in time to clinical resolution as described by the time to achieve three consecutive negative RT-PCR tests.

Furthermore, the antiviral was found to be safe and well-tolerated in the trial.

The mean change in viral load of Covid-19 from baseline to day 14 was 43,337c/mL and 7,039.7c/mL for Prothione capsules and placebo, respectively. 

The antiviral offered a marked rise of 156.9 (N95) in red blood cell GSH levels from baseline to day 29 versus 107.3 (N83) for placebo.

A substantial decline was observed in hospitalisations in subjects who received Prothione capsules with only one such case reported versus four in the placebo arm. 

This indicates that the decline in viral load aided in decreasing Covid-19 progression and severity.

Prothione CEO Laura Lile said: “With its excellent safety profile and low price point, Prothione is poised to save lives and reduce strain on health care systems around the world.”

The company is planning to enter collaboration to conclude Phase III trials in the US.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena